BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23259385)

  • 1. [Dendritic cells for cancer immunotherapy].
    Kakimi K; Kondo A; Matsushita H
    Nihon Rinsho; 2012 Dec; 70(12):2130-5. PubMed ID: 23259385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing dendritic cells for immunotherapy.
    Delamarre L; Mellman I
    Semin Immunol; 2011 Feb; 23(1):2-11. PubMed ID: 21377379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.
    Tacken PJ; Figdor CG
    Semin Immunol; 2011 Feb; 23(1):12-20. PubMed ID: 21269839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell immunobiology and potential roles in immunotherapy.
    Fadilah SA; Cheong SK
    Malays J Pathol; 2007 Jun; 29(1):1-18. PubMed ID: 19108040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current issues in dendritic cell cancer immunotherapy.
    López JA; Hart DN
    Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo.
    Villadangos JA; Schnorrer P
    Nat Rev Immunol; 2007 Jul; 7(7):543-55. PubMed ID: 17589544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
    Dullaers M; Thielemans K
    J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.
    O'Neill D; Bhardwaj N
    Methods Mol Med; 2005; 109():1-18. PubMed ID: 15585909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct ex vivo activation of T cells for analysis of dendritic cells antigen presentation.
    Belz GT
    Methods Mol Biol; 2010; 595():351-69. PubMed ID: 19941124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of dendritic cell-based vaccination against infection.
    Fajardo-Moser M; Berzel S; Moll H
    Int J Med Microbiol; 2008 Jan; 298(1-2):11-20. PubMed ID: 17719274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
    Wesa AK; Storkus WJ
    Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting dendritic cells for priming cellular immune responses.
    Gogolák P; Réthi B; Hajas G; Rajnavölgyi E
    J Mol Recognit; 2003; 16(5):299-317. PubMed ID: 14523943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
    Rossowska J; Pajtasz-Piasecka E
    Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.